Elekta expands linac production into Russia

Print Friendly, PDF & Email

Local production of high-energy linear accelerators to help meet needs of Russian cancer patients for radiation therapy

In November 2019, Elekta and Rusatom Healthcare – a subsidiary of the Russian state nuclear corporation Rosatom – signed an agreement to establish production of Elekta Infinity® linear accelerators (linacs). Infinity is used to deliver radiation therapy to treat cancerous tumors.


Dr. Richard Hausmann, President and CEO at Elekta and Alexander Shibanov, General Director, Rusatom Healthcare JSC.

Elekta’s CEO, Richard Hausmann, signed the agreement at Berlin Science Week 2019, on November 8, within a session titled: Nuclear medicine – the alchemy of modern Oncology. He said: “This partnership is important not only for Elekta to strengthen its position in Russia, but it will improve patient access to critical cancer care. By building on each company’s unique expertise, we expect to produce state-of-the-art linacs with efficient production and distribution throughout the Russian Federation.”

This cooperation is aligned with the strategic objectives of the Russian Federation’s Ministry of Health regarding improving the accessibility of nuclear medicine to patients. Elekta and Rusatom expect to produce between five to ten Elekta Infinity linacs annually. This model offers advanced technology as well as outstanding precision and effectiveness in treating cancer tumors.

These devices will initially help meet the demand for radiation therapy in the Russian Federation, and eventually in the Eurasian Customs Union. The first linacs are expected to be ready for delivery by June 2020.

For the production, the companies will take advantage of existing facilities currently owned by Rusatom Healthcare and NIITFA (Scientific Research Institute of Technical Physics and Automatization).

Learn More
Next Previous Home